![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiOBQjBrurX5Ml7D5a6kaHYLXtjDM3VwqUF8hhyJF18eSkBVC8Wtz2zqWgbxoUT84GDTvynqioh7odYg81ckPnnpqJj5BO3Ca7yc8aojFxrUBB_PCDn4ddpJxoit51qBaCtoeU-5APpVvdV/s320/tb.jpg)
-The drug will be introduced in 104 districts across five States.
-The new class of drug is a diarylquinoline that specifically targets Mycobacterial ATP synthase, an enzyme essential for the supply of energy to Mycobacterium tuberculosis and most other mycobacteria.
-Bedaquiline is being introduced at six tertiary care centres across India. These sites have advanced facilities for laboratory testing and intensive care for patients.
-Bedaquiline will be given to multi-drug resistant TB patients with resistance to either all fluoroquinolone and/or all second line injectables and extensive drug resistant TB.
Post a Comment